Rapid Change in Plaque Size, Composition, and Molecular Footprint After Recombinant Apolipoprotein A-IMilano (ETC-216) Administration

• Published in: Journal of the American College of Cardiology Vol. 51; no. 11; pp. 1104 - 1109
• Main Authors: Ibanez, Borja, MD, Vilahur, Gemma, DVM, PhD, Cimmino, Giovanni, MD, Speidl, Walter S., MD, Pinero, Antonio, MD, Choi, Brian G., MD, Zafar, M. Urooj, MD, Santos-Gallego, Carlos G., MD, Krause, Brian, PhD, Badimon, Lina, PhD, Fuster, Valentin, MD, PhD, FACC, Badimon, Juan J., PhD, FACC
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 01.03.2008
• Subjects: Cardiovascular; Internal Medicine; apo; CETP; apolipoprotein; magnetic resonance imaging; tissue factor; MRI; cholesteryl ester transfer protein; high-density lipoprotein; cyclooxygenase; COX; rApoA-I M; recombinant apolipoprotein A-I Milano and 1-palmitoyl-2-oleoyl phosphatidylcholine complexes; HDL; MMP; TF; ETC-216; recombinant apolipoprotein A-I Milano; matrix metalloproteinase; MCP; monocyte chemoattractant protein; rApoA-IM
• ISSN: 0735-1097; 1558-3597
• DOI: 10.1016/j.jacc.2007.09.071

Rapid Change in Plaque Size, Composition, and Molecular Footprint After Recombinant Apolipoprotein A-IMilano (ETC-216) Administration: Magnetic Resonance Imaging Study in an Experimental Model of Atherosclerosis Borja Ibanez, Gemma Vilahur, Giovanni Cimmino, Walter S. Speidl, Antonio Pinero, Brian G. Choi, M. Urooj Zafar, Carlos G. Santos-Gallego, Brian Krause, Lina Badimon, Valentin Fuster, Juan J. Badimon In this experimental study, serial magnetic resonance imaging evaluations of atherosclerotic plaques showed that short-term treatment (4 days) with recombinant apolipoprotein (apo) A-IMilano induced a significant plaque regression. We further show that the rapid atherosclerotic regression was accompanied by a profound change in the composition and activity of the lesions. The apoA-IMilano infusion not only reduced by 50% the density of macrophages within the plaques, but also promoted a down-regulation of markers frequently associated with plaque vulnerability. The ApoA-IMilano represents a promising intervention to be tested in future clinical trials on high-risk patients.